SuperworthX4 Pharmaceuticals EPS XFOR
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$1.20
- Latest quarter, Q2 FY26
- −$0.13
- Fiscal year 2025
- −$4.34
X4 Pharmaceuticals' earnings per share was −$1.20 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.13.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$4.34 | n/a |
| FY2024 | −$5.57 | n/a |
| FY2023 | −$18.00 | n/a |
| FY2022 | −$56.10 | n/a |
| FY2021 | −$121.20 | n/a |
| FY2020 | −$93.00 | n/a |
| FY2019 | −$287.10 | n/a |
| FY2018 | −$1704.60 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.13 | n/a | −$1.20 | |
| Q1 FY26 | −$0.16 | −500% | −$4.54 | |
| Q4 FY25 | −$0.22 | n/a | −$4.34 | |
| Q3 FY25 | −$0.69 | n/a | −$10.01 | |
| Q2 FY25 | −$3.47 | −126% | −$14.80 | |
| Q1 FY25 | $0.04 | n/a | $2.24 | |
| Q4 FY24 | −$5.89 | n/a | −$5.57 | |
| Q3 FY24 | −$5.48 | n/a | −$2.68 | |
| Q2 FY24 | $13.57 | n/a | $2.50 | |
| Q1 FY24 | −$7.77 | n/a | −$20.97 | |
| Q4 FY23 | −$3.00 | n/a | −$18.00 | |
| Q3 FY23 | −$0.30 | n/a | −$23.70 |
Against its peers
Companies in Biotechnology nearest X4 Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| XFORX4 Pharmaceuticals | −$1.20 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on X4 Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.